Announcements Trials
Browse Landscape

Phase

Phase 1 11Phase 3 2Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Patient Preference 1Inflammatory Breast Neoplasms 1

Interventions

Carboplatin 314Paclitaxel 302Cisplatin 250Docetaxel 237pembrolizumab 230Gemcitabine 213Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 120Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 92Prednisone 91Oxaliplatin 89atezolizumab 73Leucovorin 71durvalumab 69130-nm albumin-bound paclitaxel 67Injections 64Lenalidomide 63Irinotecan 60Bortezomib 55Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Injections, Subcutaneous × Clear all
NCT05296798 2026-04-16

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Hoffmann-La Roche

Phase 3 Active not recruiting
922 enrolled
Breast

Breast Neoplasms

NCT05415215 2026-02-10

ProHer

Hoffmann-La Roche

Phase 3 Completed
346 enrolled 20 charts
Breast

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡